This study is in progress, not accepting new patients

MIS-C Comparative Effectiveness Study

a study on Multisystem Inflammatory Syndrome in Adults Multisystem Inflammatory Syndrome in Children

Summary

Eligibility
for people ages up to 20 years (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Adriana Tremoulet, MD, MAS (ucsd)
Headshot of Adriana Tremoulet
Adriana Tremoulet

Description

Summary

In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus. Some children were sick enough to require care in the intensive care unit for what came to be known as Multisystem Inflammatory Syndrome-Children (MIS-C).The clinical presentation shared many features with Kawasaki disease (KD), a self-limited inflammation that can cause ballooning of the arteries of the heart. Thus, physicians reached for many of the therapies used to treat children with KD. Despite the surge of COVID-19 cases and children continuing to present with MIS-C, there are no data that guide the choice of therapy. Thus, the investigators have designed a study to determine which combination of therapies is most effective in helping children with MIS-C recover quickly.

Official Title

Multisystem Inflammatory Syndrome Therapies in Children (MISTIC) Comparative Effectiveness Study

Details

This study is a multi-site, randomized, pragmatic, comparative effectiveness study of children with MIS-C. The current standard of care is that all MIS-C patients are initially treated with IVIG and receive additional therapy if they are severely ill or do not improve clinically. This study design will randomize subjects who have received IVIG but clinically warrant further anti-inflammatory therapy to one of three treatment arms (infliximab, steroids or anakinra) and allow for re-randomization to one of the two remaining arms if clinically warranted.

Keywords

Multisystem Inflammatory Syndrome-Children, Syndrome, Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Hemisuccinate, Prednisolone, Prednisolone acetate, Infliximab, Interleukin 1 Receptor Antagonist Protein, Prednisolone hemisuccinate, Prednisolone phosphate, Anakinra, Methylprednisilone (steroids)

Eligibility

You can join if…

Open to people ages up to 20 years

  1. An individual aged <21 years presenting with
    1. Fever (>38.0°C for ≥24 hours; may be by subjective report) AND

    2. Two or more of the following (from two different systems; e.g. one from cardiac and one from mucocutaneous):

      Cardiac

      • Hypotension
      • Shock
      • Arrhythmia
      • Tachycardia
      • Left ventricular ejection fraction <55%
      • Valvulitis
      • Coronary artery enlargement (LAD or RCA Z-score ≥ 2.5)
      • Pericardial effusion Gastrointestinal
      • Diarrhea
      • Nausea/vomiting
      • Significant abdominal pain Immunologic
      • Lymphadenopathy (unilateral cervical or diffuse) Mucocutaneous
      • Bilateral conjunctival injection
      • Extremity swelling or erythema
      • Rash
      • Lip erythema/Strawberry tongue Neurologic
      • Altered mental status
      • Focal neurological deficits
      • Headache
      • Meningismus
    3. Laboratory evidence of inflammation, including but not limited to, an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase (LDH), neutrophilia, lymphopenia or hypoalbuminemia AND
    4. No alternative plausible diagnoses based on clinical judgement AND
    5. Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or suspected COVID-19 exposure AND
    6. Parent or legal guardian (or self if at least 18 years old) able and willing to provide informed consent and subject willing and able to provide assent when appropriate.

You CAN'T join if...

  1. Known immunodeficiency
  2. Pre-existing medical condition that precludes receiving one or more of the study medications (e.g. TB, drug allergy to study medication).

Locations

  • Rady Children's Hospital
    San Diego California 92123 United States
  • Children's Hospital Michigan
    Detroit Michigan 48201 United States

Lead Scientist at University of California Health

  • Adriana Tremoulet, MD, MAS (ucsd)
    Dr. Adriana (Adri) Tremoulet is Professor of Pediatrics in the Division of Host-Microbe Systems and Therapeutics in the Department of Pediatrics at UC San Diego, specializing in pediatric infectious diseases and clinical pharmacology.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT04898231
Phase
Phase 2/3 research study
Study Type
Interventional
Participants
About 73 people participating
Last Updated